Quest Diagnostics upgraded by Leerink Partners with a new price target
$DGX
Medical Specialities
Health Care
Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $195.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $185.00 | Buy → Neutral | Citigroup |
| 1/6/2025 | $169.00 → $174.00 | Market Perform → Outperform | Leerink Partners |
| 12/17/2024 | $145.00 → $172.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $175.00 → $185.00 | Buy | Jefferies |
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird |
| 8/28/2024 | $165.00 | In-line | Evercore ISI |
| 7/10/2024 | $145.00 → $165.00 | Neutral → Buy | Citigroup |
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh
SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute
JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
SCHEDULE 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)
144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care SECAUCUS, N.J., May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-initiated testing platform from Quest Diagnostics (NYSE:DGX), one of the nation's leading providers of diagnostic information services, today revealed the results of its second "Know Your Health" survey, conducted online by The Harris Poll among nearly 2,100 U.S. adults. Findings revealed that most America
SECAUCUS, N.J., May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time. The presentation session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.
SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti
First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir
SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q
Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00
Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00
Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)